Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Dulce Brito, Paulo Bettencourt, Davide Carvalho, et al.
Cardiovascular Drugs and Therapy (2020) Vol. 34, Iss. 3, pp. 419-436
Open Access | Times Cited: 23

Showing 23 citing articles:

Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs
Silviu Stanciu, Emilia Rusu, Daniela Miricescu, et al.
Metabolites (2023) Vol. 13, Iss. 1, pp. 87-87
Open Access | Times Cited: 54
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 79
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
Rosanna Maccari, Rosaria Ottanà
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 10848-10881
Open Access | Times Cited: 30
The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
Saverio Muscoli, Francesco Barillà, Rojin Tajmir, et al.
Pharmaceutics (2022) Vol. 14, Iss. 8, pp. 1730-1730
Open Access | Times Cited: 27
Applications and prospects of phosphoproteomics in renal disease research
Xuejia Zheng, Lingling Zhou, Tiantian Xu, et al.
PeerJ (2025) Vol. 13, pp. e18950-e18950
Open Access
Mitochondrial Ca2+, redox environment and ROS emission in heart failure: Two sides of the same coin?
Sonia Cortassa, Magdalena Juhaszova, Miguel A. Aon, et al.
Journal of Molecular and Cellular Cardiology (2020) Vol. 151, pp. 113-125
Open Access | Times Cited: 31
Myocardial Infarction
Mukesh Nandave
(2024), pp. 249-318
Closed Access | Times Cited: 3
Differential effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose–response meta-analysis involving 10 randomized clinical trials and 71 553 individuals
Donna Shu‐Han Lin, An‐Li Yu, Hao-Yun Lo, et al.
European Journal of Endocrinology (2023) Vol. 189, Iss. 1, pp. S17-S25
Closed Access | Times Cited: 8
Growing role of SGLT2i in heart failure: evidence from clinical trials
Ajay Varadhan, Katarina Stephan, Rahul Gupta, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 2, pp. 147-159
Closed Access | Times Cited: 13
Gender differences in new hypoglycemic drug effects on renal outcomes: a systematic review
Guido Gembillo, Valeria Cernaro, Alfio Edoardo Giuffrida, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 3, pp. 323-339
Closed Access | Times Cited: 6
SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
José Silva‐Cardoso, Aurora Andrade, Dulce Brito, et al.
Revista Portuguesa de Cardiologia (2021) Vol. 40, Iss. 9, pp. 687-693
Open Access | Times Cited: 8
Cardiac Sodium/Hydrogen Exchanger (NHE11) as a Novel Potential Target for SGLT2i in Heart Failure: A Preliminary Study
Lorena Pérez-Carrillo, Alana Aragón‐Herrera, Isaac Giménez-Escamilla, et al.
Pharmaceutics (2022) Vol. 14, Iss. 10, pp. 1996-1996
Open Access | Times Cited: 5
SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
José Silva‐Cardoso, Aurora Andrade, Dulce Brito, et al.
Revista Portuguesa de Cardiologia (English Edition) (2021) Vol. 40, Iss. 9, pp. 687-693
Open Access | Times Cited: 7
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Inês Aguiar‐Neves, Diogo Santos‐Ferreira, Ricardo Fontes‐Carvalho
Reviews in Cardiovascular Medicine (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Four aces of heart failure therapy: systematic review of established and emerging therapies for heart failure with reduced ejection fraction
E Ruffino, Mauro Gori, Emilia D’Elia, et al.
Cardiology Plus (2022) Vol. 7, Iss. 1, pp. 20-28
Open Access | Times Cited: 4
Gliflozinas: más que antidiabéticos orales. Una breve revisión de la literatura
Verónica González, Dra Verónica González, Doença Renal, et al.
Revista Uruguaya de Cardiología (2021) Vol. 36, Iss. 1
Open Access | Times Cited: 4
Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
Mauro Gori, Emilia D’Elia, Edoardo Sciatti, et al.
Cardiac failure review (2022) Vol. 8
Open Access | Times Cited: 3
Expanding the possibilities of using sodium-glucose cotransporter 2 inhibitors in patients with heart failure
Мaryana М. Rоsul, Мyroslava М. Bletskan, Nataliya V. Ivano, et al.
Wiadomości Lekarskie (2024) Vol. 77, Iss. 3, pp. 585-590
Closed Access
Management of Patients with Chronic Heart Failure and Diabetes Mellitus
Е. В. Резник, T. L. Nguyen, G. N. Golukhov
Rational Pharmacotherapy in Cardiology (2021) Vol. 17, Iss. 2, pp. 341-350
Open Access | Times Cited: 1
Gliflozinas: más que antidiabéticos orales. Una breve revisión de la literatura
Verónica González, Dra Verónica González, Doença Renal, et al.
Revista Uruguaya de Cardiología (2021) Vol. 36, Iss. 1
Open Access | Times Cited: 1
Current Trends in the Treatment of Heart Failure in Patients with Diabetes Mellitus and Ejection Fraction: An Analysis of the Relationship between SGLT2 and Heart Failure
Daniel Felipe Marin Bolívar, Javier González‐Argote
Salud Ciencia y Tecnología - Serie de Conferencias (2023) Vol. 2, pp. 321-321
Open Access
Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators
L. Papadimitriou, Gabriel A. Hernandez, Brandon Lennep, et al.
Current Treatment Options in Cardiovascular Medicine (2021) Vol. 23, Iss. 5
Closed Access
Uso de inibidores da SGLT2 em pacientes com insuficiência cardíaca com fração de ejeção reduzida / Use of SGLT2 inhibitors in heart failure patients with reduced ejection fraction
Roberta Ellen Santos Oliveira, André Álvares Figueiredo Silva, Helena Quintão de Albergaria Caus, et al.
Brazilian Journal of Health Review (2021) Vol. 4, Iss. 5
Open Access
Page 1

Scroll to top